Cornerstone Capital Management Holdings’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-33,500	Closed	-$289K	–	1416
2016 Q4	$289K	Buy	+33,500	New	+$248K	﹤0.01%	1158
2016 Q1	–	Sell	-44,500	Closed	-$273K	–	1593
2015 Q4	$273K	Sell	44,500 -28,000	-39%	-$184K	﹤0.01%	1151
2015 Q3	$415K	Buy	72,500 +52,200	+257%	+$401K	﹤0.01%	1063
2015 Q2	$151K	Sell	20,300 -400	-2%	-$2.42K	﹤0.01%	1242
2015 Q1	$124K	Sell	20,700 -29,800	-59%	-$188K	﹤0.01%	1242
2014 Q4	$382K	Buy	+50,500	New	+$302K	﹤0.01%	1009
2014 Q2	–	Sell	-3,500	Closed	-$14K	–	1434
2014 Q1	$14K	Buy	+3,500	New	+$17.9K	﹤0.01%	1293
2013 Q4	–	Sell	-8,600	Closed	-$43K	–	1355
2013 Q3	$43K	Sell	8,600 -40,800	-83%	-$221K	﹤0.01%	1191
2013 Q2	$221K	Buy	+49,400	New	+$222K	﹤0.01%	1038

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Cornerstone Capital Management Holdings's PGNX Position: Q1 2017 in Review

Cornerstone Capital Management Holdings sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2017, closing a stake of 33,500 shares — an estimated $289K sold.

Cornerstone Capital Management Holdings first reported a position in PGNX in Q2 2013 and held it in 9 quarters. The position peaked at $415K in Q3 2015. 159 funds tracked by Wall St. Rank hold PGNX as of Q1 2017.

Cornerstone Capital Management Holdings reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
Cornerstone Capital Management Holdings sold 33,500 Progenics Pharmaceuticals Inc shares in Q1 2017, an estimated $289K.
Cornerstone Capital Management Holdings first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 9 quarters.
Cornerstone Capital Management Holdings's Progenics Pharmaceuticals Inc position peaked at $415K in Q3 2015.
159 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q1 2017, filed 10 May 2017.